IL1B and deep vein thrombosis: The CANTOS (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) provided compelling evidence that targeting IL-1β with canakinumab, an IL-1β inhibitor, significantly reduced cardiovascular events independent of lipid levels, reinforcing the therapeutic potential of inflammation modulation [22,32].